Altimmune, Inc.
910 Clopper Road
Suite 210S
Gaithersburg
Maryland
20878
United States
Tel: 2406541450
Website: http://www.altimmune.com/
28 articles with Altimmune, Inc.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
-
Altimmune Presents Highlights of Intranasal COVID-19 Vaccine and Therapeutic Programs – AdCOVID™ and T-COVID™ – at the World Vaccine Congress
9/28/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Scot Roberts, Ph.D., Chief Scientific Officer of Altimmune, Inc., presented an overview of the Company’s AdCOVID and T-COVID intranasal vaccine and therapeutic candidates during a special COVID-19 virtual session of the World Vaccine Congress Washington, taking place September 28 – October 1, 2020. A link to Dr. Roberts’ presentation is availab
-
Altimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASHCompany anticipates first-in-human trials to start in Q4 2020
9/1/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the successful completion of multiple dose toxicity and toxicokinetic studies of ALT-801, a GLP-1/glucagon dual receptor agonist for the treatment of NASH. The IND enabling studies were conducted in rats and cynomolgus monkeys. The Company believes the data provide clear validation of previously observed pharmacodynamic effects of the compound and pav
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
-
Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update
8/11/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020 and provided a business update.
-
Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
8/7/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. With this milestone, the data readout for the Day 28 immunogenicity endpoint remains on target for Q4 2020. The clinical trial has enrolled 42 evaluable healthy subjects to receive intranasally administered NasoShield or
-
Altimmune Announces Manufacturing Agreement with Vigene Biosciences for AdCOVID™, its Single Dose Intranasal Vaccine Candidate for COVID-19
7/22/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company has entered into an agreement with Vigene Biosciences (“Vigene”) to manufacture AdCOVIDTM, Altimmune’s single-dose intranasal vaccine candidate for COVID-19.
-
Altimmune Announces Closing of $132 Million Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option
7/16/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its previously announced underwritten public offering of 4,119,564 shares of its common stock, and, to certain investors in lieu thereof, pre-funded warrants to purchase 1,630,436 shares of its common stock at an exercise price of $0.0001 per share.
-
Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
7/13/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock.
-
Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants
7/13/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 3,369,564 shares of its common stock and, to certain investors in lieu thereof, pre-funded warrants to purchase 1,630,436 shares of its common stock at an exercise price of $0.0001 per share.
-
Clinical Catch-Up: June 29-July 3
7/6/2020
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look. -
Clinical Catch-Up: June 22-26
6/29/2020
It was a busy week for clinical trial updates. Here’s a look. -
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update
5/13/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 and provided a business update.
-
Altimmune to Announce First Quarter 2020 Financial Results on May 14
5/8/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2020 before the market open and host a conference call on Thursday, May 14, 2020. Conference Call Details Date: Thursday, May 14 Time: 8:30 am Eastern Time Domestic: 855-327-6837 International: 631-891-4304 Conference ID: 10009533 W
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
-
Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate UpdateConference Call & Webcast Scheduled for Friday, March 27, at 8:30 am Eastern Time
3/27/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019 and provided a corporate update. “2019 was a productive year for the Company with the acquisition of ALT-801, a supplemental award for the development of NasoShield from BARDA, and the advancement of ALT-702 as a preclinical program,” said Vipin K. Garg, Ph.D., President and Chief Executive Offi
-
Altimmune to Announce Year End 2019 Financial Results on March 27
3/25/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020.
-
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
2/28/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the advancement of a novel single-dose, intranasal vaccine using Altimmune’s proprietary technology to protect against COVID-19, the disease caused by the SARS-CoV-2 virus.
-
Altimmune to Present at Upcoming Investor and Scientific Conferences
2/4/2020
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February: